Pharmaceutical giant Pfizer revealed this week that it is going to acquire Array BioPharma in a deal worth $11.4 billion. Array BioPharma, a drug developer with a product portfolio that includes a treatment combination used for advanced skin cancer that is being tested in other cancers as well, will receive $48 per share in cash. … Continue reading “Pfizer to Buy Array BioPharma for $11.4 Billion”